Chongqing Lummy Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Chongqing Lummy Pharmaceutical has been growing earnings at an average annual rate of 28.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 19% per year. Chongqing Lummy Pharmaceutical's return on equity is 1.8%, and it has net margins of 2.2%.
Key information
28.9%
Earnings growth rate
32.5%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -19.0% |
Return on equity | 1.8% |
Net Margin | 2.2% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative
Oct 29Recent updates
Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%
Nov 15We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative
Oct 29Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%
Oct 01What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You
Oct 01Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)
Feb 27Revenue & Expenses Breakdown
How Chongqing Lummy Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 856 | 19 | 550 | 90 |
30 Jun 24 | 823 | 46 | 538 | 92 |
31 Mar 24 | 850 | -10 | 560 | 94 |
31 Dec 23 | 896 | -9 | 595 | 100 |
30 Sep 23 | 858 | -86 | 575 | 80 |
30 Jun 23 | 932 | -74 | 670 | 75 |
31 Mar 23 | 913 | -46 | 657 | 72 |
01 Jan 23 | 885 | -69 | 654 | 81 |
30 Sep 22 | 1,004 | -158 | 769 | 103 |
30 Jun 22 | 1,020 | -182 | 742 | 113 |
31 Mar 22 | 1,064 | -176 | 773 | 116 |
31 Dec 21 | 1,225 | -101 | 853 | 100 |
30 Sep 21 | 1,404 | -307 | 970 | 135 |
30 Jun 21 | 1,597 | -286 | 1,058 | 118 |
31 Mar 21 | 1,695 | -270 | 1,099 | 109 |
31 Dec 20 | 1,584 | -327 | 1,039 | 107 |
30 Sep 20 | 1,632 | -231 | 1,035 | 166 |
30 Jun 20 | 1,662 | -217 | 1,059 | 165 |
31 Mar 20 | 1,795 | -184 | 1,135 | 165 |
31 Dec 19 | 1,859 | -155 | 1,113 | 164 |
30 Sep 19 | 1,801 | 74 | 1,008 | 42 |
30 Jun 19 | 1,669 | 71 | 891 | 44 |
31 Mar 19 | 1,548 | 73 | 759 | 43 |
31 Dec 18 | 1,562 | 98 | 754 | 43 |
30 Sep 18 | 1,477 | 95 | 730 | 31 |
30 Jun 18 | 1,440 | 93 | 642 | 45 |
31 Mar 18 | 1,363 | 79 | 571 | 36 |
31 Dec 17 | 1,282 | 56 | 492 | 31 |
30 Sep 17 | 1,169 | 21 | 377 | 23 |
30 Jun 17 | 1,074 | 18 | 342 | 0 |
31 Mar 17 | 990 | 10 | 311 | 0 |
31 Dec 16 | 990 | 7 | 309 | 0 |
30 Sep 16 | 966 | 53 | 285 | 0 |
30 Jun 16 | 970 | 42 | 271 | 0 |
31 Mar 16 | 974 | 34 | 267 | 0 |
31 Dec 15 | 964 | 21 | 261 | 0 |
30 Sep 15 | 999 | 40 | 230 | 0 |
30 Jun 15 | 999 | 45 | 228 | 0 |
31 Mar 15 | 992 | 36 | 230 | 0 |
31 Dec 14 | 912 | 9 | 228 | 0 |
30 Sep 14 | 820 | 1 | 223 | 0 |
30 Jun 14 | 756 | -1 | 209 | 0 |
31 Mar 14 | 743 | 19 | 205 | 0 |
31 Dec 13 | 759 | 61 | 195 | 0 |
Quality Earnings: 300006 has a large one-off loss of CN¥30.7M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 300006 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300006 has become profitable over the past 5 years, growing earnings by 28.9% per year.
Accelerating Growth: 300006 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300006 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 300006's Return on Equity (1.8%) is considered low.